Ergun, Y. Et Al. 2019. KRAS codon 12 and 13 mutations may guide the selection of irinotecan or oxaliplatin in first-line treatment of metastatic colorectal cancer. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS , vol.19, no.12 , 1131-1140.

Ergun, Y., Acikgoz, Y., Bal, O., Ucar, G., Dirikoc, M., Yildirim, E., ... Akdeniz, N.(2019). KRAS codon 12 and 13 mutations may guide the selection of irinotecan or oxaliplatin in first-line treatment of metastatic colorectal cancer. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS , vol.19, no.12, 1131-1140.

Ergun, Yakup Et Al. "KRAS codon 12 and 13 mutations may guide the selection of irinotecan or oxaliplatin in first-line treatment of metastatic colorectal cancer," EXPERT REVIEW OF MOLECULAR DIAGNOSTICS , vol.19, no.12, 1131-1140, 2019

Ergun, Yakup Et Al. "KRAS codon 12 and 13 mutations may guide the selection of irinotecan or oxaliplatin in first-line treatment of metastatic colorectal cancer." EXPERT REVIEW OF MOLECULAR DIAGNOSTICS , vol.19, no.12, pp.1131-1140, 2019

Ergun, Y. Et Al. (2019) . "KRAS codon 12 and 13 mutations may guide the selection of irinotecan or oxaliplatin in first-line treatment of metastatic colorectal cancer." EXPERT REVIEW OF MOLECULAR DIAGNOSTICS , vol.19, no.12, pp.1131-1140.

@article{article, author={Yakup Ergun Et Al. }, title={KRAS codon 12 and 13 mutations may guide the selection of irinotecan or oxaliplatin in first-line treatment of metastatic colorectal cancer}, journal={EXPERT REVIEW OF MOLECULAR DIAGNOSTICS}, year=2019, pages={1131-1140} }